USPTO Trademark 79052271
USPTO Trademark 79052271 is a USPTO trademark filed by Genmab A/S. Status: Registered.
Prosecution Summary
Trademark Summary
(No mark text provided in the record) is a service mark. It is registered under Application Number 79052271 (Registration No. 3502080) for biochemical and pharmaceutical preparations and related research/medical services centered on human monoclonal antibodies for cancer and other infectious/immune-related diseases, including immune and autoimmune diseases and inflammatory diseases (and includes references to cardiovascular diseases in several class descriptions). The registration is currently active, with a recorded status indicating that a Section 71 declaration has been accepted (status date April 2, 2019). The owner is Genmab A/S.
No opposition or TTAB/other legal proceeding is listed in the provided record.
Recent Activity
Key recent
Trademark Facts
| Mark | USPTO Trademark 79052271 |
|---|---|
| Serial Number | 79052271 |
| Registration Number | 3502080 |
| Status | Registered |
| Filing Date | 2007-07-25 |
| Registration Date | 2008-09-16 |
| Mark Type | Design |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals), 042 (Software & IT) |
| Owner | Genmab A/S |
| Attorney of Record | Max Vern |
| Prosecution Events | 40 |
| Latest Event | NREP on 2025-03-24 |
Goods & Services
Pharmaceutical preparations based on human monoclonal antibodies for use in the treatment of cancer [, AIDS, acquired immune deficiency syndrome, ] and other infectious diseases, immune and autoimmune diseases, inflammatory diseases [ and cardiovascular diseases ]; Biochemical, namely, monoclonal antibodies for in vivo or in vitro scientific research and in vivo or in vitro development in the field of cancer [, AIDS, acquired immune deficiency syndrome, ] and other infectious diseases, immune and autoimmune diseases, inflammatory diseases [ and cardiovascular diseases ]; Medical scientific research, namely, biological research into human monoclonal antibodies and development of pharmaceutical products based on human monoclonal antibodies for use in the treatment of cancer, AIDS, acquired immune deficiency syndrome, and other infectious diseases, immune and autoimmune diseases, inflammatory diseases and cardiovascular diseases; chemical analysis, patent exploitation, licensing of intellectual property in the field of medicine; computer programming, namely, programming of computers for the collection and processing of medical data in medical scientific research, development and therapy with monoclonal antibodies